{"id":"W2940105550","doi":"10.1016/j.jhepr.2019.02.001","title":"Infliximab for the treatment of refractory immune-related hepatitis secondary to checkpoint inhibitors: A case report","year":2019,"lang":"en","type":"article","venue":"JHEP Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Nivolumab; Ipilimumab; Medicine; Melanoma; Adverse effect; Immune checkpoint; Internal medicine; Immune system; Common Terminology Criteria for Adverse Events; Cancer; Oncology; Immunology; Immunotherapy; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004909578,0.0001915174,0.0004575467,0.00009763327,0.0000734382,0.00001398162,0.00003855278,0.0001205282,0.0005278175],"category_scores_gemma":[0.00008324523,0.0001238221,0.0004461091,0.0001856983,0.00008438063,0.00006686185,0.0000193891,0.00009110136,0.000008174662],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003335973,"about_ca_system_score_gemma":0.0003512572,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00475421,"about_ca_topic_score_gemma":0.0002003267,"domain_scores_codex":[0.9980018,0.00001885998,0.001184894,0.0003564726,0.0002203453,0.0002176865],"domain_scores_gemma":[0.9980112,0.000105846,0.0006466625,0.0009917209,0.0001599914,0.00008454164],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.008957367,0.003499499,0.1232621,0.0007867339,0.005123946,0.2643481,0.01333685,0.00004497225,0.2418382,0.00002386201,0.01190102,0.3268774],"study_design_scores_gemma":[0.005553607,0.005938138,0.0469308,0.0003344162,0.0004216895,0.2075005,0.0007983989,0.00006113614,0.1200931,0.00004895926,0.611949,0.0003702161],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9894383,0.003579468,0.00001626109,0.0009676056,0.001339257,0.002425589,0.00001642891,0.00004808402,0.002169012],"genre_scores_gemma":[0.9912887,0.0002591771,0.0002088408,0.0001698985,0.0001383003,0.0002527298,0.00005865991,0.00003665259,0.007587105],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.600048,"threshold_uncertainty_score":0.7186976,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01072632906009327,"score_gpt":0.2735513881588859,"score_spread":0.2628250590987927,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}